Cytokinetics (CYTK) Misses Q3 EPS by 35c

Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($1.52), $0.35 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $3.16 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
• Unifi, Inc. (UFI) Misses Q4 EPS by 11c